IBO IMPACT BIOMEDICAL INC revenue, earnings and financials
For the quarter ended June 30, 2026, IMPACT BIOMEDICAL INC reported revenue of $3.00K (down 57.1% from a year earlier), net income of −$699K and diluted EPS of −$0.01; for the fiscal year ended December 2025 revenue was $32.0K.
IBO annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $32.0K, gross profit n/a, operating income −$4.28M, net income −$11.8M (margin -36993.8%), EPS −$0.38
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$28.8M, net income −$24.7M (margin n/a), EPS −$2.30
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$4.03M, net income −$4.34M (margin n/a), EPS −$0.07
- Fiscal year ended Dec 2022: revenue $50.0K, gross profit n/a, operating income −$3.40M, net income −$7.26M (margin -14510.0%), EPS −$0.10
IBO quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $3.00K (down 57.1% year over year), net income −$699K, EPS −$0.01
- Quarter ended Mar 31, 2026: revenue $7.00K, net income −$2.29M, EPS −$0.02
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income $5.25M, EPS $1.03
- Quarter ended Sep 30, 2025: revenue $18.0K, net income −$1.47M, EPS −$0.12
- Quarter ended Jun 30, 2025: revenue $7.00K, net income −$14.3M, EPS −$1.18
- Quarter ended Mar 31, 2025: revenue n/a, net income −$1.27M, EPS −$0.11
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$27.1M, EPS −$2.17
- Quarter ended Sep 30, 2024: revenue n/a, net income $4.25M, EPS $0.06
- Quarter ended Jun 30, 2024: revenue n/a, net income −$889K, EPS −$0.09
- Quarter ended Mar 31, 2024: revenue n/a, net income −$962K, EPS −$0.10
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$1.19M, EPS −$0.02
- Quarter ended Sep 30, 2023: revenue n/a, net income −$1.18M, EPS −$0.02
- Quarter ended Jun 30, 2023: revenue n/a, net income −$1.12M, EPS −$0.02
- Quarter ended Mar 31, 2023: revenue n/a, net income −$849K, EPS −$0.01
- Quarter ended Sep 30, 2022: revenue n/a, net income −$2.24M, EPS −$0.03
- Quarter ended Jun 30, 2022: revenue $50.0K, net income −$799K, EPS $0.00
IBO cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$1.89M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$2.85M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$2.85M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$2.24M, share buybacks n/a
IBO balance sheet
- Jun 30, 2026: cash n/a, total assets $16.7M, total liabilities $2.73M, shareholders' equity $10.8M
- Mar 31, 2026: cash $20.0K, total assets $17.1M, total liabilities $2.38M, shareholders' equity $11.5M
- Dec 31, 2025: cash $3.00K, total assets $17.4M, total liabilities $1.85M, shareholders' equity $12.3M
- Sep 30, 2025: cash $12.0K, total assets $18.2M, total liabilities $27.1M, shareholders' equity −$11.8M
- Jun 30, 2025: cash $624K, total assets $19.1M, total liabilities $26.4M, shareholders' equity −$10.3M
- Mar 31, 2025: cash $1.32M, total assets $20.1M, total liabilities $13.2M, shareholders' equity $3.84M
- Dec 31, 2024: cash $2.00M, total assets $20.3M, total liabilities $13.1M, shareholders' equity $4.26M
- Sep 30, 2024: cash $2.67M, total assets $46.7M, total liabilities $12.3M, shareholders' equity $31.3M
What is IBO's revenue?
IMPACT BIOMEDICAL INC reported $32.0K of revenue for the fiscal year ended December 2025.
Is IBO profitable?
Yes. IMPACT BIOMEDICAL INC earned $789K over the last four quarters.
What is IBO's EPS?
Diluted earnings per share over the last four quarters were $0.88; −$0.01 in the latest quarter.